Drug Royalties Co. Ramps Up Issuance

Ontario-based DRI Capital is preparing a securitization from its portfolio of royalties from pharmaceutical and bio-tech patents, following up its March ABS issuance and marking an accelerated issuance strategy for the company.

  • 30 Nov 2012

Ontario-based DRI Capital is preparing a securitization from its portfolio of royalties from pharmaceutical and bio-tech patents, following up its March ABS issuance and marking an accelerated issuance strategy for the company.

DRI planned to tap the ABS market for financing in August of 2011, but shelved the ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

GlobalCapital European securitization league table

Rank Lead Manager/Arranger Total Volume $m No. of Deals Share % by Volume
1 Citi 3,237 10 19.12
2 Goldman Sachs 2,096 5 12.39
3 Morgan Stanley 1,965 5 11.61
4 BNP Paribas 1,686 6 9.96
5 Barclays 1,565 4 9.25

Bookrunners of Global Structured Finance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Citi 33,499.81 106 11.84%
2 JPMorgan 26,026.16 75 9.20%
3 Wells Fargo Securities 25,325.15 70 8.95%
4 Bank of America Merrill Lynch 23,157.33 74 8.18%
5 Barclays 17,494.57 59 6.18%